@article {Shamekhe253383, author = {Ahmed Shamekh and Colin Powell and Abdusamea Ashabani and Ibtihal Siddiq Abdelgadir}, title = {Post-COVID mRNA vaccine myocarditis in children: report of two cases}, volume = {15}, number = {11}, elocation-id = {e253383}, year = {2022}, doi = {10.1136/bcr-2022-253383}, publisher = {BMJ Specialist Journals}, abstract = {The SARS-COV-2 pandemic led to the development of several vaccinations to contain the disease. The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine was recommended on May 2021 for use in children above 12 years and older. The vaccine is safe, well tolerated and highly effective. Initial reports showed no serious adverse events; however, cases of myocarditis in young healthy male adolescents have been reported. We report two cases of myocarditis/perimyocarditis who presented with short history of chest pain following administration of the second dose of the MRN COVID-19 vaccine.}, URL = {https://casereports.bmj.com/content/15/11/e253383}, eprint = {https://casereports.bmj.com/content/15/11/e253383.full.pdf}, journal = {BMJ Case Reports CP} }